New Study Shows Promise for High-CBG Hemp Extract in Treating Inflammatory Bowel Disease
Researchers found that daily treatment with this extract significantly reduced the severity of colitis symptoms in mice.
A recent study has revealed promising results for the use of high-cannabigerol (CBG) hemp extract in treating inflammatory bowel disease (IBD). The research, conducted using a mouse model of colitis, suggests that this non-euphoric cannabis extract could offer a new treatment option for IBD patients.
The study utilized a commercially available hemp extract containing 20 mg/mL cannabigerol(CBG), 20.7 mg/mL cannabidiol(CBD), and 1 mg/mL cannabichromene(CBC). Researchers found that daily treatment with this extract significantly reduced the severity of colitis symptoms in mice.
Key findings include:
- Decreased disease activity index
- Increased colon length
- Reduced colon tissue damage
Beyond symptom management, the study also explored the extract's impact on gut health. Analysis of the fecal microbiota showed that the high-CBG hemp extract treatment led to potentially beneficial alterations in gut bacteria composition.
Furthermore, metabolomic analysis of fecal samples indicated a normalization of several metabolic pathways, including those involved in inflammation, in treated mice.
This research is particularly significant given the growing interest in cannabis-based treatments for gastrointestinal issues.
While these results are encouraging, it's important to note that this study was conducted on mice, and further research is needed to confirm these effects in humans. Nonetheless, this work provides a scientific basis for exploring high-CBG hemp extracts as a potential treatment for IBD.
As the cannabis industry continues to evolve, studies like this highlight the potential therapeutic applications of non-psychoactive cannabis compounds, opening new avenues for research and product development in the medical cannabis sector.
